Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials*

Review the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.

Andrew F. Alexis, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: August 10, 2020 Expired: August 9, 2021

With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Gain expert perspectives on the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: November 5, 2020 Expired: November 4, 2021

Introduction

Management of Moderate to Severe Atopic Dermatitis With Current Agents

Investigational Agents for the Treatment of Atopic Dermatitis

Targeted Monoclonal Antibodies for AD: Beyond Dupilumab

Questions and Answers